EUCTR2004-000644-25-SK进行中（未招募）1 期
A Phase II/III, Open-Label, Multi-Center Clinical Trial to Evaluate the Safety and Efficacy of Insulin-Like Growth Factor I/ Insulin-Like Growth Factor Binding Protein-3 (rhIGF-I/rhIGFBP-3), Administered for 12 Months in Children and Adolescents with Growth Hormone Insensitivity Syndrome (GHIS) such as Laron Syndrome.
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •See protocol page 12.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •See protocol page 12.
研究者
相似试验
已完成
2 期
Open Label Study to Evaluate tanibirumab (TTAC-001) in Patients with Recurrent GlioblastomaGlioblastomaACTRN12615001156572PharmAbcine Inc.12
进行中（未招募）
1 期
Study to identify an appropriate Modufolin® dose with respect to safety and ability to mitigate high-dose Methotrexate induced toxicity in osteosarcoma patients.EUCTR2013-001280-23-HUIsofol Medical AB18
进行中（未招募）
1 期
Study to identify an appropriate Modufolin® dose with respect to safety and ability to mitigate high-dose Methotrexate induced toxicity in osteosarcoma patients.EUCTR2013-001280-23-SEIsofol Medical AB18
进行中（未招募）
1 期
Study to identify an appropriate Modufolin® dose with respect to safety and ability to mitigate high-dose Methotrexate induced toxicity in osteosarcoma patients.Rescue after High Dose Methotrexate therapy in Osteosarcoma patients.MedDRA version: 18.1Level: PTClassification code 10061814Term: DetoxificationSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2013-001280-23-CZIsofol Medical AB18
进行中（未招募）
1 期
A first in man study of RGT100 injection into solid tumorsEUCTR2016-003028-22-DERigontec GmbH15